Estimating the Direct Medical Costs and Productivity Loss of Outpatient Chlamydia and Gonorrhea Treatment.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
25
5
2021
Statut:
ppublish
Résumé
We used 2016-2017 administrative claims data to calculate the direct medical cost and productivity loss per diagnosed case of chlamydia and gonorrhea treatment. In 2018 US dollars, the direct cost per diagnosed case was $151 for chlamydia (n = 9180) and $85 for gonorrhea (n = 3048); productivity loss was $206 (n = 31) and $246 (n = 7), respectively, among those missing work seeking care.
Identifiants
pubmed: 33448729
doi: 10.1097/OLQ.0000000000001240
pii: 00007435-202102000-00012
pmc: PMC7939516
mid: NIHMS1665217
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18-e21Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Copyright © 2020 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: None declared.
Références
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. Atlanta, GA: U.S. Department of Health and Human Services, 2019.
Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
LeFevre ML. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161:902–910.
Owusu-Edusei K, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40:197–201.
Owusu-Edusei K, Doshi SR, Apt BS, et al. The direct cost of chlamydial infections: Estimates for the employer-sponsored privately insured population in the United States, 2003–2007. Sex Transm Dis 2010; 37:519–521.
Owusu-Edusei K, Gift TL, Chesson HW. Treatment cost of acute gonococcal infections: Estimates from employer-sponsored private insurance claims data in the United States, 2003–2007. Sex Transm Dis 2010; 37:316–318.
Owusu-Edusei K, Roby TM, Chesson HW, et al. Productivity costs of nonviral sexually transmissible infections among patients who miss work to seek medical care: Evidence from claims data. Sex Health 2013; 10:434–437.
Alpern JD, Zhang L, Stauffer WM, et al. Trends in pricing and generic competition within the oral antibiotic drug market in the United States. Clin Infect Dis 2017; 65:1848–1852.
Hansen L. The Truven Health MarketScan Databases for life sciences researchers. 2017. Available at: https://truvenhealth.com/Portals/0/Assets/2017-MarketScan-Databases-Life-Sciences-ResearchersWP.pdf .
Athena—OHDSI Vocabularies Repository. Services, O. D. (2015–2019). From Odysseus Data Services, Inc. Available at: athena.ohdsi.org .
CDC. De-duplication guidance for gonorrhea and chlamydia laboratory reports. 2016. Available at: https://www.cdc.gov/std/laboratory/de-duplication-guidance-june2016.pdf .
RED BOOK Online. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com . Accessed October 29, 2019.
United States Department of Labor. Consumer Price Indexes—All Urban Consumers [Internet]. Washington, DC: United States Department of Labor. Available at: https://www.bls.gov/cpi/home.htm . Accessed February 6, 2020.
U.S. Bureau of Labor Statistics. The Employment Situation—Table B-3. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted September 2019. In: Washington, DC. Available at: https://www.bls.gov/news.release/empsit.t19.htm .
Dave CV, Brill G, Kesselheim AS. Changes in price for generic drugs in the USA, 2008–2016. J Gen Intern Med 2019; 34:1677–1679.
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006; 55:1–94.
Almalki ZS, Yue X, Xia Y, et al. Utilization, spending, and price trends for quinolones in the US Medicaid programs: 25 Years' experience 1991–2015. Pharmacoecon Open 2017; 1:123–131.
Dean LT, Montgomery MC, Raifman J, et al. The affordability of providing sexually transmitted disease services at a safety-net clinic. Am J Prev Med 2018; 54:552–558.
Li X, Hilsden R, Hossain S, et al. Validation of administrative data sources for endoscopy utilization in colorectal cancer diagnosis. BMC Health Serv Res 2012; 12:358.
Mason SA, Nathens AB, Byrne JP, et al. The accuracy of burn diagnosis codes in health administrative data: A validation study. Burns 2017; 43:258–264.
Tao G, Workowski J, Bowden K, et al. Determining recommended chlamydia and gonorrhea treatment using linked medical claims, prescription and laboratory data. Vancouver, BC, Canada: Presented at: 23rd STI & HIV 2019 World Congress [P491], 2019.
Rein DB, Kassler WJ, Irwin KL, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial. Obstet Gynecol 2000; 95:397–402.